Search

Memorial Sloan Kettering Cancer Center has appointed Gilles Salles, MD, PhD, Chief of the Lymphoma Service, Division of Hematologic Malignancies.

… Friday, November 12, 2021 Memorial Sloan Kettering Cancer Center (MSK) has appointed Gilles Salles, MD, PhD , as Chief of the Lymphoma Service, Division of Hematologic Malignancies. He succeeds Anas Younes, MD. Dr. Salles received his MD and PhD from the Université Claude Bernard Lyon and completed a

High-risk neuroblastoma cells harbor distinguishing molecular signatures, according to recent research.

… Friday, August 2, 2019 High-risk neuroblastoma cells harbor distinguishing molecular signatures, according to research that physician-scientists at Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine published recently in the journal Neoplasia. These unique characteristics distinguish neuroblastoma

Discover how MSK Monmouth is making an impact in Middletown, New Jersey.

… Wednesday, December 13, 2017 In the year since MSK Monmouth opened its doors in Middletown, New Jersey, the facility has become a vital part of the community. VIDEO | 03:45 Meet the MSK Monmouth Care Team Hear about the benefits of receiving surgery, treatment and rehabilitation close to home. Video

Lymphoma experts Anas Younes, MD and Andrew Zelenetz, MD, PhD discuss the fast evolving research on CAR T cells and checkpoint inhibitors that is yielding the novel treatment options improving both outcomes and quality of life for people with lymphoma.

… Wednesday, May 16, 2018 VIDEO | 05:17 Lymphoma Update: CAR T Therapies and Checkpoint Inhibitors Lymphoma experts Anas Younes, MD and Andrew Zelenetz, MD, PhD discuss the fast evolving research on CAR T cells and checkpoint inhibitors that is yielding the novel treatment options improving both outcomes

A new MSK-led study used single-cell sequencing and other techniques to examine a phenomenon known as “whole-genome doubling” in high-grade serous ovarian carcinoma (HGSOC), the most common and aggressive form of ovarian cancer. The insights could help researchers develop more effective treatment strategies.

… Wednesday, July 16, 2025 Research led by Memorial Sloan Kettering Cancer Center (MSK) is shedding new light on how ovarian cancer evolves — insights that could help researchers develop more effective treatment strategies. While ovarian cancer diagnoses and deaths have decreased over recent decades ,

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Monday, May 17, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Larry Norton Elected to the American Academy of Arts & Sciences Larry Norton Larry Norton, MD , Senior Vice President, Office of the President; Medical Director, Evelyn H. Lauder Breast

Discovery reveals that the genetic causes of cancer may be more complicated than previously thought.

… Wednesday, May 27, 2020 Summary It turns out that finding driver mutations may be more complicated than previously thought: Nearly a quarter of all tumors have two different mutations in the same gene. A major effort in cancer research is the search for driver mutations in tumors. These mutations are

The PICI@MSK fellowship will provide Dr. Delconte with two years of financial support for her research on natural killer cells in cancer.

… Wednesday, March 17, 2021 Rebecca Delconte is a postdoctoral fellow working in the lab of immunologist Joseph Sun in the Sloan Kettering Institute. She is the recipient of the 2021-2022 Parker Institute for Cancer Immunotherapy at MSK  Postdoctoral Fellowship, which will provide two years of financial

A new study shows that a large majority of patients who present with advanced colorectal cancer that has spread to other organs (stage IV) don't require immediate surgery to remove the primary tumor in the colon.

… Saturday, May 30, 2009 A new study shows that a large majority of patients who present with advanced colorectal cancer that has spread to other organs (stage IV) don’t require immediate surgery to remove the primary tumor in the colon. Researchers from Memorial Sloan Kettering Cancer Center (MSKCC) presented

Drugs that block the action of TGF-ß may make checkpoint inhibitors more effective.

… Friday, April 5, 2019 Summary TGF-ß, which has been studied for more than 30 years, has many jobs. One of them is helping to regulate the immune system. The immunotherapy drugs called checkpoint inhibitors have transformed treatment for some people with cancer. Currently, a major focus in cancer research